What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
A drug candidate’s chance of approval is only one input to a biotech stock’s value. Investors also need to estimate what the drug could earn if approved, when it might reach market, how much development will cost, what other assets the company owns, and whether it can finance the work without materially diluting shareholders. A promising approval probability does not, by itself, make a stock cheap.
Why approval odds and stock value are different
An approval probability describes the chance that a particular drug candidate will clear a specified regulatory path. A biotech stock represents a claim on the company’s overall equity value: the value of its pipeline and other assets, less its obligations, divided among shareholders.
The connection is the candidate’s expected future contribution to the business. An investor can estimate that contribution by modeling possible development and commercial outcomes, weighting them by their probabilities, and accounting for timing and costs. But an approval estimate alone says nothing definitive about market size, sales, financing needs, or the price investors already assign to the company.
| Measure | What it answers | What it does not answer |
|---|---|---|
| Probability of approval | How likely a candidate is to receive approval through a specified regulatory pathway, given the evidence and remaining development work. | Whether the stock is attractively priced or the drug will be commercially successful. |
| Probability of commercial success | How likely an approved product is to achieve a defined level of commercial performance under stated assumptions. | Whether shareholders will earn a positive return at the current share price. |
| Risk-adjusted asset value | What a drug program’s possible future cash flows may be worth after accounting for development risk, costs, and time. | The value of the whole company until other assets and corporate claims are considered. |
| Expected stock return | How an investor’s potential return compares with the price paid, under a set of scenarios. | A guaranteed outcome; actual results can differ sharply from modeled cases. |
What a clinical phase tells you—and what it doesn’t
A Phase 1, Phase 2, or Phase 3 label identifies a broad stage of clinical development. It is not a fixed approval probability. The remaining uncertainty depends on the disease and patient population, drug modality, trial design, endpoint, effect size, safety findings, consistency across subgroups, and the evidence regulators still require.
#1 Best Overall
The FDA’s consumer overview describes a typical sequence from preclinical work through Phase 1, Phase 2, Phase 3, and an application for review. It gives broad sample-size ranges of 20–80 participants for Phase 1, a few dozen to about 300 for Phase 2, and several hundred to about 3,000 for Phase 3. Those are general descriptions, not rules for every drug or trial. A larger or later-stage trial is not automatically decisive: its design and results still matter.
Read the evidence behind the phase label
- Trial design: Check whether the study is randomized and controlled, how many participants enrolled, and whether the population matches the patients the product is intended to treat.
- Primary endpoint: Ask whether it is clinically meaningful, whether it was prespecified, and whether the FDA has indicated that it could support the intended application.
- Results: Consider the size and uncertainty of the treatment effect, not just whether a result was described as positive. Look for durability and consistency across relevant groups.
- Safety: Weigh adverse events, discontinuations, and monitoring or risk-management needs against the expected benefit.
- Remaining evidence: Identify the next trial or other evidence needed, its expected cost and timing, and any unresolved regulatory questions.
The FDA reviews data submitted by sponsors; it does not conduct the sponsors’ clinical trials. Its 2023 benefit-risk guidance explains that review considers a drug’s benefits, risks, and risk-management options, including patient experience and how development evidence is designed and presented.
Why a generic “Phase 3 approval rate” can mislead
Historical transition rates can help set an initial prior, but pooled averages do not determine an individual candidate’s prospects. The result depends on which diseases, modalities, phases, and definitions of success went into the dataset, as well as the period studied. Miller, Rabinovitz, and Kerr specifically questioned whether rates aggregated across therapeutic areas accurately represent individual diseases.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Accordingly, there is no responsible universal percentage to attach to “Phase 3” on the evidence available here. Before using any published success rate, identify its underlying denominator, dates, population, modality mix, phases covered, and meaning of “success.” Then treat it as a starting assumption to refine using the candidate’s actual data—not as a forecast for a named stock.
What FDA designations and approval statistics mean
For U.S. FDA review, fast track, breakthrough therapy, priority review, and accelerated approval are expedited programs for certain products and circumstances. They can facilitate development or review; none guarantees approval. A designation is process context, not a substitute for trial evidence.
Accelerated approval may rely on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory evidence obligations. The FDA says whether a surrogate endpoint is acceptable for an individual drug or biologic program is determined case by case. Investors should check what endpoint supported the program, what benefit it is intended to predict, and whether confirmatory studies are required.
The FDA reported that 37 of the 50 novel drugs CDER approved in 2024 were approved on the first review cycle, and that 33 of those 50 approvals used one or more expedited programs. These are statistics about drugs that were already approved in 2024. They are not estimates of the chance that an unapproved candidate will reach approval.
How to value a drug candidate with risk-adjusted cash flows
Risk-adjusted net present value, or rNPV, is a way to estimate what a development program’s expected future cash flows may be worth today. It probability-weights cash flows by development outcomes and discounts for time and the cost of capital. WIPO’s 2025 guide describes rNPV as a widely used method for biotech assets and firms and recommends scenario analysis rather than reliance on a single outcome. A 2019 peer-reviewed model paper also describes incorporating drug type, development stage, phase attrition, and development period.
Keep development risk conceptually separate from the discount rate. If the same risk is fully reflected in both a low success probability and an unusually high discount rate, the model may count it twice. Conversely, a precise-looking rNPV is not proof of precision: attrition and development-time evidence can be limited or inconsistent in some areas, and assumptions vary by drug class and program.
Rank #4
Build the asset model in stages
- Map the program’s possible paths. Estimate the chance of reaching each next phase and the chance of eventual approval conditional on the current evidence. State the population and assumptions behind each probability. Avoid multiplying unrelated generic rates as if they described this candidate.
- Estimate timing and spending. Forecast when trials, regulatory submissions, and launch could occur, and assign development costs to the phases in which they would be incurred. Probability-weight future costs according to whether the program is expected to reach those phases.
- Model post-approval economics. Estimate addressable patients, likely uptake, competition, pricing and reimbursement, manufacturing and launch costs, and the remaining period of exclusivity. Use downside, base, and upside cases rather than treating one sales forecast as certain.
- Discount cash flows to the present. Apply a discount rate consistent with the timing and capital-cost assumptions, while keeping the model’s explicit development probabilities visible.
- Test the assumptions that matter most. Change success probabilities, readout timing, trial delays, market penetration, net price, competitor entry, development costs, discount rate, and financing needs to see what drives the result.
Approval permits marketing under the approved U.S. label; it does not guarantee sales or profitability. A product may win approval yet have limited uptake, face competition, require costly manufacturing or commercialization, or fail to generate enough revenue to recoup investment. Analysis Group’s 2024 practitioner guide illustrates probability-weighting phase-specific research and development costs and post-commercialization value, while emphasizing that inputs can vary substantially across drugs. Its case-study assumptions are examples, not universal values.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to translate asset value into a stock framework
A candidate’s rNPV is not the company’s equity value. Start with each material asset, including any credible partnership economics, and add separately supported value for other programs or platform opportunities. Then bridge from enterprise value to equity by accounting for cash, debt, liabilities, and other claims. Divide an indicative equity value by an appropriately diluted share count—not merely the current basic share count—to frame a per-share estimate.
Financing is central to that bridge. Estimate the cash needed to reach the next meaningful milestones and compare it with available cash and expected spending. If the company may need to issue shares, model how much capital it might raise and how dilution could affect existing shareholders. A favorable scientific outlook can coexist with a weak shareholder outcome if the company must raise substantial capital on unfavorable terms.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Finally, compare the scenario-implied value with the company’s market capitalization or enterprise value. Ask what success, timing, commercial uptake, and financing assumptions the current price appears to require. A lead drug should not be treated as the entire company when there are material other programs, partnerships, liabilities, or platform options.
A practical comparison checklist
- Clinical evidence: What are the design, endpoint, effect size, uncertainty, durability, and safety findings?
- Probability assumptions: Are rates asset-specific or pooled, and are their dataset, time period, denominator, and definition of success stated?
- Regulatory path: What application route and evidence burden are expected? Is there public FDA feedback, and are confirmatory obligations relevant?
- Commercial case: How many patients could be treated, what alternatives exist, and what uptake, net-price, manufacturing, and exclusivity assumptions drive projected cash flows?
- Time and cost: When are the next milestones and potential launch, what spending is required to reach them, and how would a delay affect present value and cash runway?
- Shareholder claim: What are cash, debt, burn rate, diluted shares, partnership economics, and likely financing needs?
- Market expectations: How does the company’s current valuation compare with downside, base, and upside scenarios across its portfolio?
Without a named company, candidate, indication, trial readout, financial statements, and share count, it is not possible to calculate a fair value or an approval probability for a particular stock. The comparison is a framework for testing assumptions, not a target price.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
